Schizophrenia and bipolar disorder.
The mechanism of action of Lurasidone in the treatment of schizophrenia and bipolar depression is unknown. However, its efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine Type 2 (D2) and serotonin Type-2 (5HT2A) receptor antagonism.
Schizophrenia BY MOUTH Adult: Initially 37 mg once daily, increased if necessary up to 148 mg once daily Schizophrenia when given with concomitant moderate CYP3A4 inhibitors (e.g. diltiazem, erythromycin, fluconazole, and verapamil) BY MOUTH Adult: Initially 18.5 mg once daily (max. per dose 74 mg once daily)
Lurasidone should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, etc.)
High doses in elderly . susceptibility to Qtinterval prolongation
Common or very common Anxiety . musculoskeletal stiffness Uncommon Catatonia . decreased appetite . dysarthria . dysuria . hot flush . myalgia . nightmares Frequency not known Angina .AV block . bradycardia . dysphagia . panic attacks . pruritus . suicidal behaviour . vertigo
PREGNANCY Use only if potential benefit outweighs risk? limited information available.
Store at temperature not exceeding 30°C in a dry place. Protect from light.
.png&w=384&q=75)